BioXcel Therapeutics Executive Compensation (FY24)
BTAI · Executive and director compensation, fiscal 2023 to 2024
Chief executive, fiscal 2024 ◇ Vimal Mehta | Latest say-on-pay support = December 12, 2025 |
Free for 3 days · no card
See how BioXcel Therapeutics’s pay stands against its peers
- BioXcel Therapeutics's company dashboard and its AI-written, board-ready brief, every figure cited to the filing
- Peer-group intelligence, custom peer reruns and governance screens
- Every other company we cover, with alerts when they file
No card. Nothing is charged, and the trial ends on its own. After the trial: $499/month, or $5,000/year, about two months free.
Velarion Intel, $499/month, or $5,000/year, about two months free: one seat · every company we cover · 7-day refund, with dashboards, peer screens and board-ready briefs.
The BioXcel Therapeutics brief, $299
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $299 for the board report; $449 for both.
Data as of November 13, 2026Latest filing (8-K): December 15, 2025
3 filings cited on this page
Method: intel.velarion.ai/methodology
If a report fails to generate we keep working until you have it. No refunds on one-time reports.
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
129 figures on this page: 127 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Vimal Mehta: $4,731,147 → $1,119,245 (76.3% lower)
Say-on-pay support: 77.7% → 80.4% (2.7 points higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is BioXcel Therapeutics' chief executive and what were they paid?
Vimal Mehta, Chief Executive Officer, received $1,119,245 in total compensation for fiscal 2024. Mehta's total was 76.3% lower than the $4,731,147 reported for fiscal 2023.
What was BioXcel Therapeutics' say-on-pay result?
For fiscal 2024, shareholders backed the say-on-pay proposal with 80.4% of votes cast for or against in favor at the meeting held December 12, 2025.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Vimal Mehta Chief Executive Officer | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Javier Rodriguez Senior VP and Chief Legal Officer | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Vimal Mehta Chief Executive Officer | ◇ | — | — | ◇ | — | — | ◇ | ◇ |
Javier Rodriguez Senior VP and Chief Legal Officer | ◇ | — | ◇ | ◇ | — | — | ◇ | — not reconciled |
Richard Steinhart SVP and Chief Financial Officer | ◇ | — | ◇ | ◇ | — | — | ◇ | — not reconciled |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Javier Rodriguez | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Javier Rodriguez | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Javier Rodriguez | PSU | ◇ | — | ◇ | — | — | — | — |
| Richard Steinhart | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Richard Steinhart | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Richard Steinhart | PSU | ◇ | — | ◇ | — | — | — | — |
| Vimal Mehta | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Vimal Mehta | PSU | ◇ | — | ◇ | — | — | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Vimal Mehta | PSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | July 22, 2034 | |
| Option | ◇ | — | ◇ | March 14, 2033 | |
| Option | ◇ | — | ◇ | March 14, 2032 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | March 25, 2031 | |
| RSU | ◇ | ◇ | — | — | |
| Richard Steinhart | PSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | March 14, 2033 | |
| Option | ◇ | — | ◇ | March 15, 2033 | |
| Option | ◇ | — | ◇ | March 14, 2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | March 25, 2031 | |
| Javier Rodriguez | PSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | July 22, 2034 | |
| Option | ◇ | — | ◇ | March 15, 2033 | |
| Option | ◇ | — | ◇ | March 14, 2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | August 16, 2031 | |
| Option | ◇ | — | ◇ | February 22, 2031 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2024
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
David Mack | ◇ | ◇ | — | — | — | — | ◇ |
Peter Mueller, Ph.D Board chair · Lead independent director | ◇ | — | ◇ | — | — | — | ◇ |
Sandeep Laumas, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Michal Votruba, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Michael Miller | ◇ | — | ◇ | — | — | — | ◇ |
June Bray | ◇ | — | ◇ | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2024 | December 12, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 10, 2024 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Vimal Mehta (Chief Executive Officer), FY2024 total compensation $1,119,245 (base salary $1,001,570) [exec_comp, SEC accession 0001104659-25-110491, filed 2025-11-12]What this page does not include
Everything above is a fact BioXcel Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $299Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $299Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
129 figures on this page: 127 cited to the filing that reported them, 2 calculated from figures it prints.
127 cited to the filing
2 calculated from the filing
Documents cited
- 0001104659-25-121180Proposal 3 — Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers.
- 0001104659-25-110491DIRECTOR COMPENSATION · Outstanding Equity Awards at Year End · Summary Compensation Table
- 0001104659-24-070503Item 3 — Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers (“Say-on-Pay Vote”).
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “BioXcel Therapeutics executive compensation, FY2023–FY2024.” https://intel.velarion.ai/comp/BTAI (accessed 2026).
Short form: data: Velarion
The BioXcel Therapeutics brief, $299
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $299 for the board report; $449 for both.
3 filings cited on this page
Method: intel.velarion.ai/methodology
If a report fails to generate we keep working until you have it. No refunds on one-time reports.
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about BioXcel Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}